It's a while since I've posted here, as we've had an eventful and somewhat unsetting few months.
Tony started on Enzalutamide last November. Despite an early course of Docetaxel, which had ended in April, his PSA had started to climb again by July, and was rocketing in October (from 18 to 130 in a month), with aches and pains starting again. At first the Enza worked really well - the pains stopped, PSA dropped dramatically to less than 4, and we were able to enjoy a happy family Christmas. But by February, PSA started to shoot up again.
Our onco suggested trying the Royal Marsden to see if there were any suitable drug trials. This was a big undertaking, as we live in Devon, but Tony was prepared to give it a go. He was tested for the BRAC gene, which would have made him a good candidate for the olaparib trial, but doesn't have the gene. He was also being tested for another trial, but by this time his blood counts were too low and the cancer in his bones developing too rapidly. All this took a couple of months, during which time his PSA shot from 32 to 168. The Royal Marsden recommended, and our onco agreed, that he should start cabazitaxel asap, and within a week of this, he had his first infusion (yesterday). The good news is that despite the extensive and aggressive bone mets, there is still no significant lymph involvement, no sign of SCC, and his liver and other organs are clear. He is tired and his joints are stiff, but the pain hasn't returned.
So we're off on another stage of treatment. Tony will have cabazitaxel for up to ten cycles, or for as long as it is tolerable and beneficial. He's also having Zometa infusions now. So far he feels OK and is currently outside, working at his beehives. All the rules on hygiene and diet are having to be attended to once again, which is a bit daunting and socially limiting, but at least there will be a pattern to the treatment now, and after a couple of cycles (if it's working) we will know what to expect and be able to plan around it. We hope to have some good times yet.